EMEA-001410-PIP01-12 - paediatric investigation plan

ixazomib citrate

Key facts

• Active Substance:
  ixazomib citrate
• Therapeutic area:
  Haematology-Hemostaseology
• Decision number:
  P/0159/2013
• PIP number:
  EMEA-001410-PIP01-12
• Pharmaceutical form(s):
  Capsule (hard)
• Condition(s) / indication(s):
  Treatment of systemic light chain amyloidosis
• Route(s) of administration:
  Oral use
• Contact for public enquiries:

  Takeda Global Research & Development Centre (Europe) Ltd

  United Kingdom; E-mail: [e-mail]; Tel. [phone]

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  05/07/2013

Decision

P/0159/2013: EMA decision of 5 July 2013 on the granting of a product-specific waiver for ixazomib (citrate) (EMEA-001410-PIP01-12)

AdoptedReference Number: EMA/332034/2013